A phase I dose-finding and pharmacokinetics study of CPC634 (nanoparticle entrapped docetaxel) in patients with advanced solid tumors.

Florence Atrafi,Herlinde Dumez,Ron H.J. Mathijssen,Catharina Wilhelmina Menke,Jo Costermans,Cristianne J.F. Rijcken,Rob Hanssen,Ferry A.L.M. Eskens,Patrick Schöffski

A phase I dose-finding and pharmacokinetics study of CPC634 (nanoparticle entrapped docetaxel) in patients with advanced solid tumors.

2019

Florence Atrafi
Herlinde Dumez
Ron H.J. Mathijssen
Catharina Wilhelmina Menke
Jo Costermans
Cristianne J.F. Rijcken
Rob Hanssen
Ferry A.L.M. Eskens
Patrick Schöffski

3026Background: CPC634 is a novel product with docetaxel temporarily entrapped within stabilized CriPec nanoparticles. We performed the first-in-human study with CPC634 (NCT02442531). Methods: Pati...

Keywords:

Nanoparticle
Cancer research
Pathology
Docetaxel
Pharmacokinetics
Medicine
in patient
Urology
dose finding

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations